All In Biotech

NDA 050814 · Gilead

Cayston

Aztreonam · Inhalation

Orphan

Last checked: Nov 20, 2026Latest source record: Nov 20, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Feb 22, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

66

34 Phase 3, 9 recruiting

FAERS reports

6,555

4,815 serious, 854 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 1, 2025.

CAYSTON ® is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa . Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV 1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pseudomonas aeruginosa in the lungs. CAYSTON is a monobactam antibacterial indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa . Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV 1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia . ( 1 )

Mechanism: Aztreonam is an antibacterial drug [see Clinical Pharmacology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CAYSTON · AZTREONAM 75MG/VIAL · FOR SOLUTION, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aztreonam" as an intervention, any sponsor and status, largest first.

All 66 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • infective pulmonary exacerbation of cystic fibrosis851
  • dyspnoea432
  • hospitalisation394
  • off label use365
  • cough353
  • cystic fibrosis287
  • pneumonia279
  • death277
  • pyrexia257
  • infection249
  • condition aggravated205
  • haemoptysis187

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
200525
200634
200720
200820
200927
201048
201168
2012122
2013327
2014340
2015294
2016360
2017384
2018617
20191,172
2020968
2021413
2022281
2023295
2024303
2025219
2026196

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cayston (Aztreonam Lysine)

2024 spending

$34.4M

Beneficiaries

770

2,903 claims

Per beneficiary

$44,704

$141.21 per unit

View as table
YearSpending
2020$35,176,831
2021$32,352,665
2022$31,792,682
2023$34,207,409
2024$34,421,839

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 291 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.